Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Therapix Biosciences Ltd ADR TRPXY

Healthcare Biotechnology
Therapix Biosciences Ltd is a specialty clinical-stage pharmaceutical company. It is engaged in developing several innovative immunotherapy products and it owns patents in the immunotherapy field. It is focused on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. The operating segments of the group are Development of drugs based on cannabinoid molecules to be approved by an official regulatory authority (the Company's operation); and Pain clinic


OTCPK:TRPXY - Post by User

Therapix Biosciences Ltd ADR > News Release
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(2)
•••
Comment by Mining_Engineer_UBCon Dec 03, 2018 11:26am
28 Views
Post# 29054233

RE:RE:RE:RE:RE:RE:RE:RE:News Release

RE:RE:RE:RE:RE:RE:RE:RE:News ReleaseVery astute post Fundy. I see things very similarly. When all is said and done this stock will make for an interesting case study. I picked up more shares today at 5.16 on the way down. We always new this stock was going to $4 or $13 (speaking in very loose terms). I suspect we will find out which one very soon!
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities